NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter FEMINGTON, N.J., April 15 /PRNewswire-FirstCall/ -- Gary Shangold, MD, chief executive officer of NovaDel Pharma, Inc. (BULLETIN BOARD: NVDL) , will be interviewed by Wall Street Reporter, a web-based financial site, tomorrow morning, Friday April 16. Dr. Shangold will provide an update on the regulatory filing plans for the company's first lingual spray product and discuss the status of product development programs for the company's Tier One candidates. These include lingual spray formulations of Zofran(R) (ondansetron), the leading anti-emetic marketed in the US by GlaxoSmithKline, Imitrex(R) (sumatriptan) also marketed in the US by GlaxoSmithKline, Ambien(R) (zolpidem) marketed in the US by Sanofi, and Xanax(R) (alprazolam), which is sold by Pfizer and several generic producers. To listen to the interview, visit http://www.wallstreetreporter.com/. The interview is expected to be posted by 11:00 a.m. EDT, Friday, April 16. About NovaDel Pharma Inc. NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. Contact: Barry C. Cohen VP Business & New Product Development 908 782-3431 x 2160 NovaDel Pharma Inc. Thomas Redington 203 222-7399 212 926-1733 DATASOURCE: NovaDel Pharma, Inc. CONTACT: Barry C. Cohen, VP Business & New Product Development of NovaDel Pharma Inc., +1-908 782-3431, ext. 2160; or Thomas Redington, +1-203 222-7399, +1-212-926-1733, , for NovaDel Pharma, Inc. Web site: http://www.wallstreetreporter.com/

Copyright